Business
Monsenso delivers digital research platform for groundbreaking UK depression project
Monsenso delivers digital research platform for groundbreaking UK depression
About this update from Monsenso A/s
[{"type":"text","content":"24.7.2025 08:30:01 CEST | Monsenso |\n Investor NewsUniversity of Birmingham, Mental Health Mission Midlands Translational Centre, Birmingham and Solihull NHS Foundation Trust and Nottinghamshire Healthcare NHS Foundation implement Monsenso's digital health platform for the DECODE project, which aims to improve the understanding and treatment of treatment-resistant depression.Investor News no. 1-2025Copenhagen, 2025.07.24(This message includes inside information)\nMonsenso A/S, a leading provider of digital health solutions, is proud to announce its strategic role as the digital technology partner for theDECODE project in the United Kingdom. \nThe initiative, led by the University of Birmingham, in collaboration with the Mental Health Mission Midlands Translational Centre, Birmingham and Solihull NHS Foundation Trust, and Nottinghamshire Healthcare NHS Foundation Trust, is focused on transforming clinical research and care for patients with treatment-resistant depression (TRD).\nAs part of the project, Monsenso’s digital platform will enable stratified recruitment, remote patient data collection, and standardised clinical endpoint measurement across multiple NHS sites — laying the groundwork for improved precision in depression research and future interventions.Addressing a Critical Public Health Challenge\nTreatment-resistant depression (TRD) affects almost half of patients diagnosed with major depressive disorder meaning they do not respond to two or more oral antidepressants, and TRD is associated with poorer outcomes, including high comorbidity, suicidality, and economic burden. [1]\nThe DECODE project aims to build a digitally enabled recruitment and monitoring infrastructure to better identify, understand, and ultimately treat this complex condition.\nRecruitment is expected to begin in Q3 2025, with Monsenso’s platform playing a pivotal role in data collection and patient stratification.\n“We are honoured to support such an important national initiative addressing one of the most challenging areas in mental health. Monsenso’s platform is designed to help healthcare providers and researchers make better, data-driven decisions through real-time digital monitoring and standardised assessments,” says Thomas Lethenborg, CEO of Monsenso. “This project reaffirms our strategic positioning as a trusted partner in supporting d...